title: Single centre experience with surgical treatment of hilar cholangiocarcinoma.
abstract: BACKGROUND /AIMS: Surgical resection is a radical treatment option for hilar cholangiocarcinomas. However it is still difficult to cure and patient prognosis is poor. An evaluation of the surgical options and results may elucidate effective treatments.
  
  
  METHODS
  We retrospectively examined the demographic characteristics, surgical records and outcome in 64 patients with hilar cholangiocarcinoma undergoing surgical resections or palliative surgical procedures for the period of 2004-2012.
  
  
  RESULTS
  The patients included 43 males and 17 females with a mean age of 61.4 Â± 10.4 years (Â±SD, range 35-81 years). Forty four resections were done - R0-22 cases (34.4%), R1 - 10 (15.6 %) cases, R2 -12 cases (18.7%) and 20 palliative (31.3%) operations were performed. R0 - resection of common bile ducts with right hepatectomy with Sg 1 was done in 8 cases, resection of common hepatic duct with left hepatectomy with Sg 1 in 9 cases and resection of common hepatic duct in 5 cases. The total percentage of postoperative morbidity is 51.5 %. The types of complications are as follows: intra abdominal bleeding 31.25 %, temporary biliary leakage - 26.56 %, leakage of hepatico-jejunostomyâ7.81 %, biliary fistula 7.81%, liver insufficiency 17.18 %, pleural effusion 48.13 %, intraabdominal abscess 28.13 %, surgical site infection 48.3 %. The mean five-year overall survival for R0 - resection is 32%, for R1 - and R2 - resection is 12% and for the palliative operations - 0%. The mean overall survival for R0-resection is 37 months, for R1 - and R2 - resection is 19 months and for the palliative operations 7 months.
  
  
  CONCLUSIONS
  Radically extended surgical resection for hilar cholangiocarcinoma is necessary to obtain improved patient survival.
authors.affiliation: Department of Hepato-Biliary Surgery and Transplantation, Military Medical Hospital, Sofia, Bulgaria. nvladov@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Vladov
authors.forename: Ts
authors.initials: Ts
authors.lastname: Lukanova
authors.forename: I
authors.initials: I
authors.lastname: Takorov
authors.forename: V
authors.initials: V
authors.lastname: Mutafchiyski
authors.forename: I
authors.initials: I
authors.lastname: Vasilevski
authors.forename: S
authors.initials: S
authors.lastname: Sergeev
authors.forename: E
authors.initials: E
authors.lastname: Odisseeva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery*; D002031:Bulgaria / Q000453:epidemiology; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D003135:Common Bile Duct / Q000601:surgery; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome